Glenmark Pulls Back 1,200 Bottles Of Hypertension Drug From US
As per the US Food and Drug Administration (USFDA), Glenmark Pharmaceuticals is in the process of recalling 1,200 bottles of a generic drug which is used in the treatment of high blood pressure, in the US market due to a manufacturing fault.
Based in New Jersey the wholly-owned arm of the company is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, according to the Enforcement Report of the US health regulator.
The batch in question was manufactured at the Goa plant of the Mumbai-based drug maker and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA stated. Glenmark is initiating the recall as the affected bottles are designated as "Subpotent" by the top US regulator.
Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, the USFDA's report added.
The company's stock was trading in green in the early hours of Tuesday, the stock was trading 0.49 per cent higher at Rs 770.75 per scrip as of 09:57 IST on BSE.
